首页> 外文期刊>Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research >Reconstituting telomerase activity using the telomerase catalytic subunit prevents the telomere shorting and replicative senescence in human osteoblasts.
【24h】

Reconstituting telomerase activity using the telomerase catalytic subunit prevents the telomere shorting and replicative senescence in human osteoblasts.

机译:使用端粒酶催化亚基重建端粒酶活性可防止端粒缩短和人类成骨细胞中的复制性衰老。

获取原文
获取原文并翻译 | 示例
           

摘要

The rate of bone formation is largely determined by the number of osteoblasts, which in turn is determined by the rate of replication of progenitors and the life span of mature cells, reflecting the timing of death by apoptosis. However, the exact age-dependent changes of the cellular activity, replicative potential, and life span of osteoblasts have not been investigated to date. Here, we present evidence that the cellular activity, telomere lengths, and replicative life span of osteoblastic cells obtained from juxta-articular bone marrow gradually decrease with the advance of donor age. Recently, telomerase reverse transcriptase (hTERT) has been identified as a human telomerase catalytic subunit. We transfected the gene encoding hTERT into telomerase-negative human osteoblastic cells from donors and osteoblastic cell strain NHOst 54881 cells and showed that expression of hTERT induces telomerase activity in these osteoblastic cells. In contrast to telomerase-negative control cells, which exhibited telomere shortening and senescence after 10-15 population doublings, telomerase-expressing osteoblastic cells had elongated telomere lengths and showed continued alkaline phosphatase activity and procollagen I C-terminal propeptide (PICP) secretion for more than 30 population doublings. These results indicate that osteoblasts with forced expression of hTERT may be used in cell-based therapies such as ex vivo gene therapy, tissue engineering, and transplantation of osteoblasts to correct bone loss or osteopenia in age-related osteoporotic diseases.
机译:骨形成的速率主要取决于成骨细胞的数量,而成骨细胞的数量又取决于祖细胞的复制速率和成熟细胞的寿命,反映出细胞凋亡的死亡时间。然而,迄今为止,尚未研究成骨细胞的细胞活性,复制潜力和寿命的确切的年龄依赖性变化。在这里,我们提供证据表明,随着供体年龄的增长,从近关节骨髓获得的成骨细胞的细胞活性,端粒长度和复制寿命得以逐渐降低。最近,端粒酶逆转录酶(hTERT)已被鉴定为人类端粒酶催化亚基。我们从供体和成骨细胞株NHOst 54881细胞中将编码hTERT的基因转染到端粒酶阴性的人类成骨细胞中,并显示hTERT的表达在这些成骨细胞中诱导了端粒酶活性。与端粒酶阴性对照细胞在10-15倍的群体倍增后表现出端粒缩短和衰老相反,表达端粒酶的成骨细胞具有延长的端粒长度,并显示出持续的碱性磷酸酶活性和前胶原I C端前肽(PICP)的分泌。超过30倍的人口。这些结果表明,具有hTERT强制表达的成骨细胞可用于基于细胞的治疗,例如离体基因治疗,组织工程和成骨细胞移植,以纠正年龄相关性骨质疏松性疾病中的骨丢失或骨质减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号